Top-Rated StocksTop-RatedNASDAQ:SNDX Syndax Pharmaceuticals (SNDX) Stock Forecast, Price & News $12.64 -0.86 (-6.37%) (As of 10/3/2023 ET) Add Compare Share Share Today's Range$12.48▼$13.4850-Day Range$12.64▼$21.6352-Week Range$12.48▼$29.86Volume4.46 million shsAverage Volume956,696 shsMarket Capitalization$878.23 millionP/E RatioN/ADividend YieldN/APrice Target$35.70 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Syndax Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside182.4% Upside$35.70 Price TargetShort InterestBearish10.92% of Shares Sold ShortDividend StrengthN/ASustainability-1.12Upright™ Environmental ScoreNews Sentiment0.38Based on 18 Articles This WeekInsider TradingSelling Shares$3.74 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.94) to ($2.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.40 out of 5 starsMedical Sector243rd out of 966 stocksPharmaceutical Preparations Industry88th out of 436 stocks 4.5 Analyst's Opinion Consensus RatingSyndax Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.70, Syndax Pharmaceuticals has a forecasted upside of 182.4% from its current price of $12.64.Amount of Analyst CoverageSyndax Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.92% of the outstanding shares of Syndax Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverSyndax Pharmaceuticals has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Syndax Pharmaceuticals has recently increased by 9.05%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSyndax Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyndax Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSyndax Pharmaceuticals has received a 66.26% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Syndax Pharmaceuticals is -1.12. Previous Next 3.0 News and Social Media Coverage News SentimentSyndax Pharmaceuticals has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Syndax Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest9 people have searched for SNDX on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.MarketBeat Follows5 people have added Syndax Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Syndax Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,742,083.00 in company stock.Percentage Held by InsidersOnly 4.70% of the stock of Syndax Pharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Syndax Pharmaceuticals are expected to grow in the coming year, from ($2.94) to ($2.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syndax Pharmaceuticals is -5.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syndax Pharmaceuticals is -5.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyndax Pharmaceuticals has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Syndax Pharmaceuticals (NASDAQ:SNDX) StockSyndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Read More SNDX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNDX Stock News HeadlinesOctober 4, 2023 | americanbankingnews.comRobert W. Baird Cuts Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $28.00October 4, 2023 | americanbankingnews.comSyndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $43.00October 4, 2023 | Legacy Research (Ad)Elon Did It Again: This Could be Bigger than TeslaLove him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.October 4, 2023 | americanbankingnews.comScotiabank Lowers Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $36.00October 4, 2023 | americanbankingnews.comSyndax Pharmaceuticals (NASDAQ:SNDX) Hits New 1-Year Low Following Analyst DowngradeOctober 3, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Teladoc (TDOC)October 3, 2023 | markets.businessinsider.comSyndax Pharmaceuticals Receives Buy Rating Following Promising AUGMENT-101 Study Results for Revumenib in Acute Leukemia TreatmentOctober 3, 2023 | americanbankingnews.comSyndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $42.00 at HC WainwrightOctober 4, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...October 2, 2023 | proactiveinvestors.comSyndax Pharmaceuticals shares fall despite positive leukemia trialOctober 2, 2023 | proactiveinvestors.comSyndax Pharmaceuticals fall despite positive leukemiaOctober 2, 2023 | finance.yahoo.comSyndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim AnalysisOctober 1, 2023 | americanbankingnews.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 2.5% September 29, 2023 | marketwatch.comSyndax Pharmaceuticals Shares Rise 15% Ahead of Study ResultsSeptember 29, 2023 | finance.yahoo.comSyndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023September 28, 2023 | americanbankingnews.comSyndax Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:SNDX)September 28, 2023 | americanbankingnews.comSyndax Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:SNDX)September 27, 2023 | finance.yahoo.comWe Think Syndax Pharmaceuticals (NASDAQ:SNDX) Can Afford To Drive Business GrowthSeptember 20, 2023 | benzinga.comLooking At Syndax Pharmaceuticals's Recent Unusual Options ActivitySeptember 8, 2023 | seekingalpha.comSyndax Pharmaceuticals: Positive Axatilimab Phase 2 ResultsAugust 31, 2023 | finance.yahoo.comSyndax Announces Participation at the Citi 18th Annual BioPharma ConferenceAugust 16, 2023 | msn.comJP Morgan Maintains Syndax Pharmaceuticals (SNDX) Overweight RecommendationAugust 8, 2023 | markets.businessinsider.comSyndax Pharmaceuticals (SNDX) Gets a Buy from Robert W. BairdAugust 4, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Syndax Pharmaceuticals (SNDX)August 3, 2023 | finance.yahoo.comSyndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business UpdateAugust 2, 2023 | msn.comSyndax Pharmaceuticals (SNDX) Price Target Increased by 8.43% to 37.29July 28, 2023 | msn.comScotiabank Initiates Coverage of Syndax Pharmaceuticals (SNDX) with Sector Outperform RecommendationSee More Headlines Receive SNDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SNDX Company Calendar Last Earnings8/03/2023Today10/04/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SNDX CUSIPN/A CIK1395937 Webwww.syndax.com Phone(781) 419-1400Fax781-419-1420Employees107Year FoundedN/APrice Target and Rating Average Stock Price Forecast$35.70 High Stock Price Forecast$43.00 Low Stock Price Forecast$28.00 Forecasted Upside/Downside+182.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-149,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-39.08% Return on Assets-36.69% Debt Debt-to-Equity RatioN/A Current Ratio13.56 Quick Ratio13.56 Sales & Book Value Annual Sales$139.71 million Price / Sales6.29 Cash FlowN/A Price / Cash FlowN/A Book Value$7.76 per share Price / Book1.63Miscellaneous Outstanding Shares69,480,000Free Float66,218,000Market Cap$878.23 million OptionableOptionable Beta1.19 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Michael A. Metzger M.B.A. (Age 52)CEO & Director Comp: $1.05MMr. Keith Alan Goldan CPA (Age 52)CFO, Treasurer & Chief Accounting Officer Comp: $649.07kMr. Luke J. Albrecht (Age 43)Sr. VP, Gen. Counsel & Sec. Comp: $605.82kDr. Catherine Madigan M.D. (Age 51)Chief Medical Officer Comp: $764.41kMr. Steve M. Sabus (Age 57)Chief Commercial Officer Comp: $523.44kDr. Peter Ordentlich B.Sc. (Age 54)Ph.D., Co-Founder & Chief Scientific Officer Dr. Richard A. Heyman Ph.D. (Age 66)Co-Founder Dr. Ronald M. Evans Ph.D.Co-Founder, Advisor and Chair of Scientific Advisory BoardDr. Michael Downes Ph.D.Co-FounderSharon KlahreVP of Investor Relations & CommunicationsMore ExecutivesKey CompetitorsArdelyxNASDAQ:ARDXInnovivaNASDAQ:INVARevance TherapeuticsNASDAQ:RVNCAvadel PharmaceuticalsNASDAQ:AVDLProtagonist TherapeuticsNASDAQ:PTGXView All CompetitorsInsiders & InstitutionsBarclays PLCSold 812,691 shares on 9/21/2023Ownership: 0.244%California State Teachers Retirement SystemBought 648 shares on 8/21/2023Ownership: 0.101%Nuveen Asset Management LLCBought 9,710 shares on 8/16/2023Ownership: 0.232%Bayesian Capital Management LPSold 995 shares on 8/15/2023Ownership: 0.025%Royal Bank of CanadaBought 1,202 shares on 8/15/2023Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions SNDX Stock - Frequently Asked Questions Should I buy or sell Syndax Pharmaceuticals stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SNDX shares. View SNDX analyst ratings or view top-rated stocks. What is Syndax Pharmaceuticals' stock price forecast for 2023? 9 Wall Street analysts have issued 12-month target prices for Syndax Pharmaceuticals' shares. Their SNDX share price forecasts range from $28.00 to $43.00. On average, they predict the company's share price to reach $35.70 in the next year. This suggests a possible upside of 182.4% from the stock's current price. View analysts price targets for SNDX or view top-rated stocks among Wall Street analysts. How have SNDX shares performed in 2023? Syndax Pharmaceuticals' stock was trading at $25.45 at the start of the year. Since then, SNDX stock has decreased by 50.3% and is now trading at $12.64. View the best growth stocks for 2023 here. When is Syndax Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our SNDX earnings forecast. How were Syndax Pharmaceuticals' earnings last quarter? Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) announced its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.09. During the same quarter last year, the business earned ($0.62) earnings per share. What ETFs hold Syndax Pharmaceuticals' stock? ETFs with the largest weight of Syndax Pharmaceuticals (NASDAQ:SNDX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI).Simplify Health Care ETF (PINK). What other stocks do shareholders of Syndax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU). When did Syndax Pharmaceuticals IPO? (SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers. What is Syndax Pharmaceuticals' stock symbol? Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX." How do I buy shares of Syndax Pharmaceuticals? Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Syndax Pharmaceuticals' stock price today? One share of SNDX stock can currently be purchased for approximately $12.64. How much money does Syndax Pharmaceuticals make? Syndax Pharmaceuticals (NASDAQ:SNDX) has a market capitalization of $878.23 million and generates $139.71 million in revenue each year. The company earns $-149,340,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis. How many employees does Syndax Pharmaceuticals have? The company employs 107 workers across the globe. How can I contact Syndax Pharmaceuticals? Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The official website for the company is www.syndax.com. The company can be reached via phone at (781) 419-1400, via email at ir@syndax.com, or via fax at 781-419-1420. This page (NASDAQ:SNDX) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.